AtheroGenic LipoprothEinS in Ischemic Stroke: The AGELESS Study

AtheroGenic LipoprothEinS in Ischemic Stroke: The AGELESS Study - AGELESS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55996

Enrollment

Registered

2023-09-12

Start date

2024-01-01

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carotid narrowing Carotid stenosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age > 18 years - Atherosclerotic carotid stenosis NASCET 30 - 99% - Ability to undergo a neck MR for carotid plaque imaging - Ability to undergo a follow-up of at least 1 year - For the prospective, longitudinal part: hemispheric ischemic stroke or retinal ischemia ipsilateral to the carotid stenosis, with symptom onset within 24 hours. - Written informed consent

Exclusion criteria

Exclusion criteria: - Carotid stenosis due to causes other than atherosclerosis (e.g. carotid dissection) - Contraindication to MRI - Lack of informed consent by patient or legal representative

Design outcomes

Primary

Measure	Time frame
For the first aim, the endpoint is presence of carotid IPH on MR-Plaque imaging at baseline. Baseline means either acquired during the hospitalization for the index stroke or during the enrolling visit at the outpatient consultation of the neurovascular clinic.	—

Secondary

Measure	Time frame
For the second aim, the endpoint is an ischemic, hemispheric, ipsilateral stroke, i.e. on the same side of the carotid stenosis, on baseline brain MR-DWI. For the third aim, the endpoint is a recurrent ischemic, hemispheric, ipsilateral stroke in the 3-month follow-up brain MR-DWI or at any time during the follow-up. The 3-month follow-up brain MR-DWI is conceived to detect covert strokes, i.e. clinically asymptomatic strokes, as recurrences tend to occur short after the first stroke.	—

Measure

Time frame

For the second aim, the endpoint is an ischemic, hemispheric, ipsilateral stroke, i.e. on the same side of the carotid stenosis, on baseline brain MR-DWI. For the third aim, the endpoint is a recurrent ischemic, hemispheric, ipsilateral stroke in the 3-month follow-up brain MR-DWI or at any time during the follow-up. The 3-month follow-up brain MR-DWI is conceived to detect covert strokes, i.e. clinically asymptomatic strokes, as recurrences tend to occur short after the first stroke.

—

Countries

Netherlands

Outcome results